Conjugate vaccines for preventing Haemophilus influenzae type B infections

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Swingler, George ^a   Fransman, D ^b   Hussey, G ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NONE

Author keywords

Developing countries; Haemophilus infections *prevention control ; Haemophilus influenzae type b; Haemophilus vaccines *therapeutic use ; Polysaccharides, bacterial *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFLUENZA; MORTALITY; PROPHYLAXIS; REVIEW; RISK FACTOR; SOCIOECONOMICS; UNSPECIFIED SIDE EFFECT;

EID: 35948951297     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001729.pub2     Document Type: Review

References (10)

1. Adams 1993 Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline in Haemophilus influenzae type b (Hib) diseases in the Hib vaccine era. JAMA 1993;269(2):264-6.
2. Asensi 1995 Asensi F, Otero MC, Perez-Tamarit D, Miranda J, Pico L, Nieto A. Economic aspects of a general vaccination against invasive disease caused by Haemophilus inflkuenzae Type B (Hib) via the experience of the Children's Hospital La Fe, Valencia, Spain. Vaccine 1995;13(16): 1563-6.
3. Barbour 1995 Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccines on carriage of Haemophilus influenzae type b. Journal of Infectious Diseases 1995;171(1):93-8.
4. CDC 1996 Center for Disease Control. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1987-1995. MMWR 1996;45:901.
5. Higgins 2005 Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; APPENDIX 5b. The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2005.
6. Mahoney 1999 Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine 1999;17(7-8):646-52.
7. Moulton 2000 Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. International Journal of Epidemiology 2000;29(4):753-6.
8. Peltola 1992 Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 1992;340:592-4.
9. Peltola 2000 Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of polysaccharide vaccine and a decade after the advent of conjugates. Clinical Microbiology Reviews 2000;13(2): 302-17.
10. Swingler 2003 Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type b infections. Cochrane Database of Systematic Reviews 2003, Issue 4.